Facebook Linkedin Soundcloud Twitter Vimeo Xing
Home Tags DREAMM trials

Tag: DREAMM trials

ASCO 2022: Belantamab Mafodotin in the Treatment of Patients with Relapsed/Refractory...

ADC Review | Editorial Team
The treatment patients diagnosed with relapsed or relapsed/refractory multiple myeloma (RRMM), those who have relapsed or who are refractory to at least 1 line of...

Belantamab Mafodotin Receives Priority Review for Relapsed or Refractory Multiple Myeloma

ADC Review | Editorial Team
The United States Food and Drug Administration (FDA) has granted a priority review of a Biologics License Application (BLA) for belantamab mafodotin (GSK2857916), a...
ADC Review, Journal of Antibody-drug Conjugates
ADC Review, Journal of Antibody-drug Conjugates (ISSN 2327-0152) is an international peer-reviewed publication designed to serve the needs of a diverse community of individuals including academia, life sciences, pharma, research, clinicians and physicians. Along with regulatory affairs, we also cover government authorities and representatives from payers to policymakers.

Latest

Peer Review

© 2013-2020 Sunvalley Communication, LLC. All Rights Reserved.

X